4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) - 75 or 98.7 mg/m2 emulsion will be administered IV once every 21-days until relapse

Advanced Cancer

Brain Metastases

DM-CHOC-PEN administration by IV infusion

DM-CHOC-PEN

Tulane University Medical Center

DM-CHOC-PEN for Brain Tumors in AYA Subjects

A Phase II: Safety and Tolerance of 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Adolescent and Young Adults (AYA) With Malignancies Involving the CNS

Blood levels for DM-CHOC-PEN and metabolites will be measured before and after each treatment; HPLC procedures will be involved.

All data regarding subject enrollment will be coded and electronically submitted to DEKK-TEC for submission to the FDA. Other trial sites are being evaluated. After all are chosen a decision will be made.

DEKK-TEC, Inc.

4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) - 39-89.7 MG/M2 iv once and then 3-weeks later radiation - 15-30 Gy will be administered

4-Demethyl-4-cholesteryloxycarbonylpenclomedine

Tulane University Medical School

Detroit Clinical Research Centers

DM-CHOC-PEN Plus Radiation for Brain Tumors

A Phase I Trial to Evaluate Safety and Tolerance of Intravenous 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Adult Subjects With Cancer Involving the CNS

Laboratory and imaging studies to verify responses

National Cancer Institute (NCI)

A Phase I Trial of DM-CHOC-PEN in Adolescent and Young Adult (AYA) Subjects With Advanced Cancers

A Phase I Trial to Evaluate Safety and Tolerance of Intravenous 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Adolescent and Young Adults (AYA) Subjects With Cancers

pyridine/sarcoma

DM-CHOC-PEN for Brain Tumors in AYA Subjects

DM-CHOC-PEN Plus Radiation for Brain Tumors

A Phase I Trial of DM-CHOC-PEN in Adolescent and Young Adult (AYA) Subjects With Advanced Cancers

Il database di erbe medicinali più completo supportato dalla scienza